Bayer has added another phase 3 trial into its registration programme for oral Factor XIa inhibitor asundexian, signalling growing confidence in a drug that generated mixed results in phase 2. The new ...

Investopedia contributors come from a range of backgrounds, and over 25 years there have been thousands of expert writers and editors who have contributed. Robert Kelly is managing director of XTS ...

Ask the publishers to restore access to 500,000+ books. The Internet Archive keeps the record straight by preserving government websites, news publications, historical documents, and more. If you find ...